SPOTLIGHT: Hikma buying Ribosepharm
Hikma Pharmaceuticals is buying Germany's Ribosepharm for $45 million in cash. Ribosepharm markets injectable generic oncology drugs. Report
Hikma Pharmaceuticals is buying Germany's Ribosepharm for $45 million in cash. Ribosepharm markets injectable generic oncology drugs. Report
Comments